Difference between revisions of "Penpulimab (Anniko)"
Jump to navigation
Jump to search
(Created page with "'''Note: Penpulimab is approved in China, but does not appear to have a brand name at this time.''' ==Mechanism of action== PD-1 inhibitor ==Diseases for which it is used== *...") |
m |
||
Line 6: | Line 6: | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
− | ==History of changes in | + | ==History of changes in NMPA indication== |
− | *8/5/2021: Approved for treatment of patients with relapsed or refractory (“r/r”) classic Hodgkin’s lymphoma (“cHL”) after at least second-line systemic chemotherapy treatment. | + | *8/5/2021: Approved for treatment of patients with relapsed or refractory (“r/r”) [[Hodgkin lymphoma|classic Hodgkin’s lymphoma (“cHL”)]] after at least second-line systemic chemotherapy treatment. |
==Also known as== | ==Also known as== |
Revision as of 22:06, 6 February 2023
Note: Penpulimab is approved in China, but does not appear to have a brand name at this time.
Mechanism of action
PD-1 inhibitor
Diseases for which it is used
History of changes in NMPA indication
- 8/5/2021: Approved for treatment of patients with relapsed or refractory (“r/r”) classic Hodgkin’s lymphoma (“cHL”) after at least second-line systemic chemotherapy treatment.
Also known as
- Code name: AK105